Kiniksa Pharma Files 2025 Proxy Statement
Ticker: KNSA · Form: DEFA14A · Filed: May 28, 2025 · CIK: 1730430
| Field | Detail |
|---|---|
| Company | Kiniksa Pharmaceuticals International, PLC (KNSA) |
| Form Type | DEFA14A |
| Filed Date | May 28, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, annual-meeting, shareholder-voting
Related Tickers: KNSA
TL;DR
Kiniksa Pharma dropped its 2025 proxy statement, shareholders vote soon.
AI Summary
Kiniksa Pharmaceuticals International, plc filed a Definitive Proxy Statement (DEFA14A) on May 28, 2025, for its 2025 Annual Meeting of Shareholders. The filing details the company's proxy materials, which are used to solicit shareholder votes on various corporate matters. The company is based in London and operates in the pharmaceutical preparations industry.
Why It Matters
This filing is crucial for shareholders as it outlines the agenda for the annual meeting and provides information needed to make informed voting decisions on company matters.
Risk Assessment
Risk Level: low — This is a routine proxy filing and does not contain new financial information or significant corporate actions that would inherently increase risk.
Key Players & Entities
- Kiniksa Pharmaceuticals International, plc (company) — Registrant
- 2025 Annual Meeting of Shareholders (event) — Subject of the proxy statement
- May 28, 2025 (date) — Filing date
- London (location) — Company headquarters
FAQ
What is the purpose of this DEFA14A filing?
The purpose of this DEFA14A filing is to serve as a Definitive Proxy Statement for the 2025 Annual Meeting of Shareholders of Kiniksa Pharmaceuticals International, plc, soliciting shareholder votes.
When was this filing made with the SEC?
This filing was made with the SEC on May 28, 2025.
What is the company's primary industry?
The company's primary industry is Pharmaceutical Preparations, with SIC code 2834.
Where is Kiniksa Pharmaceuticals International, plc located?
The company's business and mailing address is 23 Old Bond Street, Floor 3, London, WIS 4PZ.
What is the SEC file number for this filing?
The SEC file number for this filing is 001-38492.
Filing Details
This Form DEFA14A (Form DEFA14A) was filed with the SEC on May 28, 2025 regarding Kiniksa Pharmaceuticals International, plc (KNSA).